The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four
Pharmaceutical & Biotechnology Companies Provide Early Knowledge-building Opportunities for KOLs and Clinical Investigators Understanding the value that key opinion leaders provide pharmaceutical and biotechnology companies is clear, but how do companies benefit thought leaders and clinical investigators? By definition, KOLs are physicians, scientists and academics who devote time to studying and advancing their craft. Often, …
The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four Read More »
